R
Rohan Hettiarachchi
Researcher at Boehringer Ingelheim
Publications - 4
Citations - 2503
Rohan Hettiarachchi is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Dabigatran & Randomized controlled trial. The author has an hindex of 4, co-authored 4 publications receiving 2435 citations.
Papers
More filters
Journal ArticleDOI
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Bengt I. Eriksson,Ola E. Dahl,Nadia Rosencher,Andreas A. Kurth,C Niek van Dijk,Simon P. Frostick,Martin H. Prins,Rohan Hettiarachchi,Stefan Hantel,Janet Schnee,Harry R. Büller +10 more
TL;DR: Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile.
Journal ArticleDOI
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Bengt I. Eriksson,Ola E. Dahl,Nadia Rosencher,Andreas A. Kurth,C. N. Van Dijk,Simon P. Frostick,Peter Kälebo,Anita Vedel Christiansen,Stefan Hantel,Rohan Hettiarachchi,Janet Schnee,Harry R. Büller +11 more
TL;DR: Dabigatran etexilate (220 mg or 150‰mg) was at least as effective as enoxaparin and had a similar safety profile for prevention of VTE after total knee replacement surgery.
Journal ArticleDOI
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
Bengt I. Eriksson,Ola E. Dahl,Harry R. Büller,Rohan Hettiarachchi,Nadia Rosencher,Bravo Ml,Lennart Ahnfelt,Piovella F,Joachim Stangier,Peter Kälebo,Paul A. Reilly +10 more
TL;DR: In this paper, a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral Dabigatran etexilate (50, 150,mg twice daily, 300,mg once daily, 225, mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) starting 12 h prior to surgery.
Journal ArticleDOI
A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).
Bengt I. Eriksson,Ola E. Dahl,Cornelis N. van Dijk,Simon P. Frostick,Andreas A. Kurth,Nadia Rosencher,Janet Schnee,Rohan Hettiarachchi,Anita Vedel Christiansen,Stefan Hantel,Harry R. Büller +10 more
TL;DR: Oral administration of dabigatran etexilate once daily, given early in the postoperative period, was effective and safe for the prevention of total VTE in patients undergoing total knee replacement surgery.